Patient characteristics for plasma miRNA analysis
| Characteristic | Patients with CRC (n = 130) | Healthy controls (n = 75) | Patients with IBD (n = 20) | Patients with GC (n = 20) |
| No of patients | No of patients | No of patients | No of patients | |
| Age (years) | ||||
| Mean | 71 | 69 | 71 | 68 |
| Median (range) | 73 (42–91) | 70 (45–85) | 73 (61–80) | 72 (50–86) |
| Gender | ||||
| Male | 68 | 39 | 10 | 8 |
| Female | 62 | 36 | 10 | 12 |
| TNM stage inmiRNA profiling (n = 5) | – | |||
| III | 4 | – | – | – |
| IV | 1 | – | – | – |
| TNM stage inpre- and post-Op study (n = 10) | ||||
| II | 1 | – | – | – |
| III | 7 | – | – | – |
| IV | 2 | – | – | – |
| TNM stage inselected marker validation (n = 25) | – | – | ||
| III | 5 | – | – | – |
| IV | 20 | – | – | – |
| TNM stage inlarge-scale validation (n = 90) | ||||
| I | 6 | – | – | – |
| II | 34 | – | – | – |
| III | 23 | – | – | – |
| IV | 27 | – | – |
CRC, colorectal cancer; GC, gastric cancer; IBD, inflammatory bowel disease; TNM, tumour–node–metastsis staging system.